Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease

Atherosclerosis

Volumn 233, Issue 2, 2014, Pages 713-720

  Williams, Paul T ^a   Zhao, Xue Qiao ^b   Marcovina, Santica M ^c   Otvos, James D ^d   Brown, B Greg ^b   Krauss, Ronald M ^e  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d LIPOSCIENCE INC   (United States)

^e CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

Angiography; Coronary artery disease; High density lipoproteins; Lipoprotein subfractions; Low density lipoproteins; Prevention; Very low density lipoproteins

Indexed keywords

APOLIPOPROTEIN B; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; LIPOPROTEIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; COMPARATIVE STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE COURSE; FEMALE; FOLLOW UP; GEL ELECTROPHORESIS; GRADIENT GEL ELECTROPHORESIS; HUMAN; HUMAN TISSUE; ION MOBILITY SPECTROMETRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; VERTICAL AUTO PROFILE ULTRACENTRIFUGATION; BLOOD; CLASSIFICATION; ELECTROSPRAY MASS SPECTROMETRY; PROTEIN ELECTROPHORESIS; RADIOGRAPHY; RISK FACTOR; ULTRACENTRIFUGATION;

BLOOD PROTEIN ELECTROPHORESIS; CHOLESTEROL, HDL; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; RISK FACTORS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; ULTRACENTRIFUGATION;

EID: 84896301841     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.01.034     Document Type: Article

References (33)

1. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
2. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease and prevention in clinical practice. Atherosclerosis 2003, 171:145-155. Third Joint Force of European and other Societies on Cardiovascular Disease and Prevention in Clinical Practice.
3. McPherson R., Frohlich J., Fodor G., Genest J. Canadian Cardiovascular Society position statement: recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 2006, 22:913-927. Canadian Cardiovascular Society.
4. Krauss R.M., Burke D.J. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. JLipid Res 1982, 23:97-104.
5. Berneis K.K., Krauss R.M. Metabolic and clinical significance of LDL subclasses. JLipid Res 2002, 43:1363-1379.
6. Krauss R.M. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol 2010, 21:305-311.
7. Ip S., Lichtenstein A.H., Chung M., Lau J., Balk E.M. Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann Intern Med 2009, 15:474-484.
8. Parish S., Offer A., Clarke R., et al. Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation 2012, 125:2469-2478. Heart Protection Study Collaborative Group.
9. Davidson M.H., Ballantyne C.M., Jacobson T.A., et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. JClin Lipidol 2011, 5:338-367.
10. Jeyarajah E.J., Cromwell W.C., Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 2006, 26:847-870.
11. Otvos J.D., Collins D., Freedman D.S., et al. Low density lipoprotein and high density lipoprotein subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Vaterans Affairs High Density Lipoprotein Intervention Trial. Circulation 2006, 113:1556-1563.
12. Kulkarni K.R., Garber D.W., Marcovina S.M., Segrest J.P. Quantification of cholesterol in all lipoprotein classes by the VAP-II method. JLipid Res 1994, 35:159-168.
13. Caulfield M.P., Li S., Lee G., et al. Direct determination of lipoprotein particle sizes and concentrations by ion mobility analysis. Clin Chem 2008, 54:1307-1316.
14. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes. NEngl J Med 1992, 326:242-250.
15. Brown B.G., Zhao X.Q., Chait A., et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. NEngl J Med 2001, 345:1583-1592.
16. Williams P.T., Zhao X.Q., Marcovina S.M., Brown B.G., Krauss R.M. Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS). PLoS One 2013, 8(2):e56782.
17. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. NEngl J Med 1990, 323:1289-1298.
18. Rainwater D.L., Mitchell B.D., Comuzzie A.G., Haffner S.M. Relationship of low-density lipoprotein particle size and measures of adiposity. Int J Obes Relat Metab Disord 1999, 23:180-189.
19. Kulkarni K.R., Garber D.W., Jones M.K., Segrest J.P. Identification and cholesterol quantification of low density lipoprotein subclasses in young adults by VAP-II methodology. JLipid Res 1995, 36:2291-2302.
20. Kulkarni K.R., Marcovina S.M., Krauss R.M., Garber D.W., Glasscock A.M., Segrest J.P. Quantification of HDL2 and HDL3 cholesterol by the Vertical Auto Profile-II (VAP-II) methodology. JLipid Res 1997, 38:2353-2364.
21. Lounila J., Ala-Korpela M., Jokisaari J. Effects of orientational order and particle size on the NMR line positions of lipoproteins. Phys Rev 1994, 72:4049-4052.
22. Caulfield M.P., Li S., Lee G., et al. Concerns regarding lipoprotein particle measurement by ion mobility analysis. Clin Chem 2008, 54:2088-2089. In reply.
23. Williams P.T., Superko H.R., Haskell W.L., et al. Smallest LDL particles are most strongly related to coronary disease progression in men. Arterioscler Thromb Vasc Biol 2003, 23:314-321.
24. Mora S., Otvos J.D., Rifai N., Rosenson R.S., Buring J.E., Ridker P.M. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation 2009, 19:931-939.
25. Mora S., Szklo M., Otvos J.D., et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2007 May, 192(1):211-217.
26. Musunuru K., Orho-Melander M., Caulfield M.P., et al. Ion mobility analysis of lipoprotein subfractions identifies three independent axes of cardiovascular risk. Arterioscler Thromb Vasc Biol 2009, 29:1975-1980.
27. Campos H., Moye L.A., Glasser S.P., Stampfer M.J., Sacks F.M. Low-density lipoprotein size, pravastatin treatment, and coronary events. JAMA 2001, 286:1468-1474.
28. El Harchaoui K., van der Steeg W.A., Stroes E.S., et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. JAm Coll Cardiol 2007, 49:547-553.
29. Campbell D.J., Neal B.C., Chalmers J.P., et al. Low-density lipoprotein particles and risk of intracerebral haemorrhage in subjects with cerebrovascular disease. Eur J Cardiovasc Prev Rehabil 2007, 14:413-418.
30. Campos H., Roederer G.O., Lussier-Cacan S., Davignon J., Krauss R.M. Predominance of large LDL and reduced HDL2 cholesterol in normolipidemic men with coronary artery disease. Arterioscler Thromb Vasc Biol 1995, 15:1043-1048.
31. Boekholdt S.M., Arsenault B.J., Mora S., et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012, 307:1302-1309.
32. Mora S., Wenger N.K., Demicco D.A., et al. Determinants of residual risk in secondary prevention patients treated with high-versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation 2012, 125:1979-1987.
33. AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. NEngl J Med 2011, 365:2255-2267.